# Ologen (OculusGen)-Glaucoma MMC Control in Pakistan

> **NCT00472810** · PHASE3 · COMPLETED · sponsor: **Pro Top & Mediking Company Limited** · enrollment: 40 (actual)

## Conditions studied

- Glaucoma
- Trabeculectomy

## Interventions

- **DEVICE:** ologen collagen matrix in glaucoma filtering surgery
- **DRUG:** MMC in glaucoma filtering surgery

## Key facts

- **NCT ID:** NCT00472810
- **Lead sponsor:** Pro Top & Mediking Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472810, "Ologen (OculusGen)-Glaucoma MMC Control in Pakistan". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00472810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*